On November 7, 2024 Noetik, an AI-native biotech company leveraging self-supervised machine learning and high-throughput spatial data to develop next-generation cancer therapeutics, reported the first two presentations of its AI-enabled drug discovery platform at Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 39th Annual Meeting (Press release, Noetik AI, NOV 7, 2024, View Source [SID1234647997]). The posters showcase Noetik’s OCTO foundation model of cell and tissue biology and demonstrate for the first time the application of OCTO to therapeutics discovery.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Noetik’s platform brings together one of the largest multimodal spatial datasets of human tumor biology, generated in-house at Noetik labs, with custom-built self-supervised models that are trained at a scale to unlock the complexities of biology. The work at SITC (Free SITC Whitepaper) showcases, for the first time, how we can use these models as powerful engines for drug discovery," said Lacey Padron, Ph.D., Chief Technical Officer of Noetik and presenter.
SITC, a leading member-driven organization dedicated to improving cancer patient outcomes by advancing cancer immunotherapy, will host its 2024 Annual Meeting from November 6th to 10th at the George R. Brown Convention Center in Houston. The abstracts will be published in the Journal for ImmunoTherapy of Cancer (JITC).
Details on Noetik’s poster presentations at SITC (Free SITC Whitepaper) are as follows:
Title: Foundation Models of Cell and Tissue Biology Enabled by Custom Scaled Data Generation: Insights from 1000 Lung Tumor Samples
Abstract Number: 1231
Date: Friday, November 8
Location: Houston George R. Brown Convention Center – Level 1 – Exhibit Halls AB or online at View Source
Title: Multimodal foundation model of human lung tumors identifies tertiary lymphoid structures (TLS) and reveals novel therapeutic targets that promote anti-tumor immune response
Abstract Number: 861
Date: Friday, November 8
Location: Houston George R. Brown Convention Center – Level 1 – Exhibit Halls AB or online at View Source
To learn more about OCTO, visit View Source
To learn more about our comprehensive patient dataset, visit View Source